JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Home・Akciju saraksts・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Slēgts

4.17 -1.42

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.1

Max

4.19

Galvenie mērījumi
By Trading Economics
Ienākumi	4M -3.8M
Pārdošana	522K 1.1M
EPS	-0.014
Peļņas marža	-357.374
Darbinieki	19
EBITDA	75K -7.6M

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 13. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	67M 906M
Iepriekšējā atvēršanas cena	5.59
Iepriekšējā slēgšanas cena	4.17

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

3.255 / 3.365 Atbalsts un pretestība

Arbutus Biopharma Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. apr. 19:19 UTC

Iegādes, apvienošanās, pārņemšana

Intertek Group Rejects EQT's Revised Offer

2026. g. 24. apr. 23:37 UTC

Iegādes, apvienošanās, pārņemšana

Scoring the Cook Era -- Barrons.com

2026. g. 24. apr. 20:51 UTC

Iegādes, apvienošanās, pārņemšana

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026. g. 24. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 24. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 24. apr. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026. g. 24. apr. 20:09 UTC

Peļņas

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

2026. g. 24. apr. 19:48 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

2026. g. 24. apr. 19:25 UTC

Iegādes, apvienošanās, pārņemšana

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026. g. 24. apr. 19:25 UTC

Iegādes, apvienošanās, pārņemšana

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

2026. g. 24. apr. 19:22 UTC

Peļņas

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

2026. g. 24. apr. 19:06 UTC

Peļņas

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

2026. g. 24. apr. 19:05 UTC

Tirgus saruna

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

2026. g. 24. apr. 18:30 UTC

Iegādes, apvienošanās, pārņemšana

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

2026. g. 24. apr. 18:28 UTC

Iegādes, apvienošanās, pārņemšana

Intertek Rejects Revised EQT Offer

2026. g. 24. apr. 18:12 UTC

Tirgus saruna

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

2026. g. 24. apr. 18:06 UTC

Tirgus saruna

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

2026. g. 24. apr. 17:42 UTC

Peļņas

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

2026. g. 24. apr. 17:28 UTC

Peļņas

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

2026. g. 24. apr. 17:28 UTC

Tirgus saruna

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

2026. g. 24. apr. 17:12 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 24. apr. 17:11 UTC

Tirgus saruna

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

2026. g. 24. apr. 17:09 UTC

Tirgus saruna

Peļņas

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

2026. g. 24. apr. 17:09 UTC

Iegādes, apvienošanās, pārņemšana

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026. g. 24. apr. 17:06 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

2026. g. 24. apr. 16:51 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

2026. g. 24. apr. 16:20 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 24. apr. 16:20 UTC

Tirgus saruna

Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 24. apr. 16:20 UTC

Tirgus saruna

Peļņas

Auto & Transport Roundup: Market Talk

2026. g. 24. apr. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Arbutus Biopharma Corp Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Arbutus Biopharma Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.255 / 3.365Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.